Abstract:Immune checkpoint inhibitors (ICIs), Ipilimumab, Nivolumab, Pembrolizumab and Atezolizumab, have been applied in anti-tumor therapy and demonstrated exciting performance compared to conventional treatments. However, the unsatisfactory response rates, high recurrence and adaptive resistance limit their benefits. Metabolic reprogramming appears to be one of the crucial barriers to immunotherapy. The deprivation of required nutrients and altered metabolites not only promote tumor progression but also confer dysfunction on immune cells in the tumor microenvironment (TME). Glycolysis plays a central role in metabolic reprogramming and immunoregulation in the TME, and many therapies targeting glycolysis have been developed, and their combinations with ICIs are in preclinical and clinical trials. Additional attention has been paid to the role of amino acids, lipids, nucleotides and mitochondrial biogenesis in metabolic reprogramming and clinical anti-tumor therapy. This review attempts to describe reprogramming metabolisms within tumor cells and immune cells, from the aspects of glycolysis, amino acid metabolism, lipid metabolism, nucleotide metabolism and mitochondrial biogenesis and their impact on immunity in the TME, as well as the significance of targeting metabolism in anti-tumor therapy, especially in combination with ICIs. In particular, we highlight the expression mechanism of programmed cell death (ligand) 1 [PD-(L)1] in tumor cells and immune cells under reprogramming metabolism, and discuss in detail the potential of targeting key metabolic pathways to break resistance and improve the efficacy of ICIs based on results from current preclinical and clinical trials. Besides, we draw out biomarkers of potential predictive value in ICIs treatment from a metabolic perspective.

Metabolic reprogramming in the tumor microenvironment: unleashing T cell stemness for enhanced cancer immunotherapy

Metabolic Reprogramming of Immune Cells in the Tumor Microenvironment

Advances in reprogramming of energy metabolism in tumor T cells

Targeting metabolism to enhance immunotherapy within tumor microenvironment

Metabolic interventions: A new insight into the cancer immunotherapy

Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy

Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment

Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity

Metabolic reprogramming in tumor immune microenvironment: Impact on immune cell function and therapeutic implications

Unlocking the potential: Targeting metabolic pathways in the tumor microenvironment for Cancer therapy

Metabolic Crosstalk in the Tumor Microenvironment Regulates Antitumor Immunosuppression and Immunotherapy Resisitance.

Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy

Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints

Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy

Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer

Reprogramming T-Cell Metabolism for Better Anti-Tumor Immunity

Unlocking the potential of T‐cell metabolism reprogramming: Advancing single‐cell approaches for precision immunotherapy in tumour immunity

Editorial: Tumor microenvironment and metabolic reprogramming in cancer